MicroRNA-218 Is Deleted and Downregulated in Lung Squamous Cell Carcinoma by Davidson, Morgan R. et al.
MicroRNA-218 Is Deleted and Downregulated in Lung
Squamous Cell Carcinoma
Morgan R. Davidson
1,2*, Jill E. Larsen
1,2, Ian A. Yang
1,2, Nicholas K. Hayward
3, Belinda E. Clarke
2,4,
Edwina E. Duhig
4, Linda H. Passmore
1, Rayleen V. Bowman
1,2, Kwun M. Fong
1,2
1Department of Thoracic Medicine, The Prince Charles Hospital, Brisbane, Queensland, Australia, 2Discipline of Medicine, University of Queensland, Brisbane,
Queensland, Australia, 3Oncogenomics Laboratory, Queensland Institute of Medical Research, Brisbane, Queensland, Australia, 4Department of Anatomical Pathology,
The Prince Charles Hospital, Brisbane, Queensland, Australia
Abstract
MicroRNAs (miRNAs) are a family of small, non-coding RNA species functioning as negative regulators of multiple target
genes including tumour suppressor genes and oncogenes. Many miRNA gene loci are located within cancer-associated
genomic regions. To identify potential new amplified oncogenic and/or deleted tumour suppressing miRNAs in lung cancer,
we inferred miRNA gene dosage from high dimensional arrayCGH data. From miRBase v9.0 (http://microrna.sanger.ac.uk),
474 human miRNA genes were physically mapped to regions of chromosomal loss or gain identified from a high-resolution
genome-wide arrayCGH study of 132 primary non-small cell lung cancers (NSCLCs) (a training set of 60 squamous cell
carcinomas and 72 adenocarcinomas). MiRNAs were selected as candidates if their immediately flanking probes or host
gene were deleted or amplified in at least 25% of primary tumours using both Analysis of Copy Errors algorithm and fold
change ($61.2) analyses. Using these criteria, 97 miRNAs mapped to regions of aberrant copy number. Analysis of three
independent published lung cancer arrayCGH datasets confirmed that 22 of these miRNA loci showed directionally
concordant copy number variation. MiR-218, encoded on 4p15.31 and 5q35.1 within two host genes (SLIT2 and SLIT3), in a
region of copy number loss, was selected as a priority candidate for follow-up as it is reported as underexpressed in lung
cancer. We confirmed decreased expression of mature miR-218 and its host genes by qRT-PCR in 39 NSCLCs relative to
normal lung tissue. This downregulation of miR-218 was found to be associated with a history of cigarette smoking, but not
human papilloma virus. Thus, we show for the first time that putative lung cancer-associated miRNAs can be identified from
genome-wide arrayCGH datasets using a bioinformatics mapping approach, and report that miR-218 is a strong candidate
tumour suppressing miRNA potentially involved in lung cancer.
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Introduction
MiRNAs are a highly conserved family of small non-coding
RNA species that negatively regulate gene expression via RNA
interference. Calin et al first identified two miRNAs (miR-15 and
miR-16) within 13q14, a region frequently deleted in chronic
lymphocytic leukaemia, with significantly reduced expression [1].
Since then, altered miRNA expression has been reported in
numerous malignancies, including colon [2,3], breast [4,5], lung
[6,7,8], liver [9], brain [10,11], lymphoma [12,13,14] and
leukaemia [1,15,16].
In lung cancer, studies have identified the tumour suppressing
let-7 family and the oncogenic miR-17-92 cluster of miRNAs. The
let-7 family is consistently downregulated in primary lung tumours
and lung cancer cell lines, which abrogates let-7’s control on RAS,
allowing RAS overexpression, thereby contributing to lung
carcinogenesis [6,7,17]. Significant overexpression of the onco-
genic miR-17-92 cluster of miRNAs occurs in lung cancer cell lines
and tumours [18], where miR-17-92 miRNAs are upregulated by
oncogenic c-Myc and act as part of a regulatory network balancing
cell death and proliferation with c-Myc and E2F1 [19,20,21].
MiRNAs demonstrate complex patterns of genomic organisa-
tion with both intergenic and intragenic miRNA genes [22,23].
Calin et al reported that most known miRNAs are in regions of
genomic aberration associated with cancer [17]. In keeping, let-7
and miR-17-92 are linked to chromosomal deletions and gains
respectively, indicating copy number variations as potential
mechanisms for their dysregulation in lung tumours [17,21,24].
We reasoned that novel dysregulated lung cancer miRNAs can be
identified by virtue of somatically acquired aberrant gene dosage, and
this allows the large number of publically available unbiased genome-
wide arrayCGH datasets to be exploited for identification of miRNAs
involved in disease even though the original studies were not
specifically designed for miRNA loci. Using this strategy we report
for the first time, identification of miR-218 (hsa-miR-218; MI-
MAT0000275) located within a region of genomic loss (4p15.31 and
5q35.1) as a putative tumour suppressor in non-small cell lung cancer
(NSCLC). MiR-218 was recently identified as a tumour suppressor in
PLoS ONE | www.plosone.org 1 September 2010 | Volume 5 | Issue 9 | e12560cervical cancer [25] where its downregulation was linked with human
papilloma virus (HPV) [25]. Although we observed a significant
reduction in miR-218 in subjects with a history of cigarette smoking
we found no relationship between HPV and miR-218 in lung SCCs.
Materials and Methods
Clinical Specimens
Resected primary NSCLC and corresponding normal lung tissue
were obtainedwithinformedwritten consent frompatients undergoing
lung resection at The Prince Charles Hospital between 1990 and 2007
(Human Research Ethics Committee 9124). Clinicopathological data
was available for all specimens as previously published including
disease recurrence [26,27] and asbestos fibre burden [28].
ArrayCGH Detection of Chromosomal Aberration
ArrayCGH data for 132 curatively resected primary NSCLCs
(training set) was provided by Dr JE Larsen (manuscript in
preparation) (Table 1) using the Agilent Human Genome CGH
Microarray 44B (Agilent, G4410B) platform and tumour sample
hybridisation against normal female DNA (Human Genomic DNA
Female, Promega G152A) according to the manufacturer’s instruc-
tions. Filtered, normalised signal log ratios between lung tumour
DNA and normal female reference DNA were used for analyses.
For robust detection of DNA copy number aberrations, two
independent bioinformatic approaches were used: i) Fold change
(FC) of +/21.2 (high discovery sensitivity) in individual probe
intensity using signal log ratios (Affymetrix, Statistical Algorithms
Reference Guide); and ii) CGH Explorer Analysis of Copy Errors
(ACE) algorithm [29] controlling significance and false discovery
rate at ,0.001 to avoid Type 1 error for multiple comparisons.
Adenocarcinomas (AC) (n=72) and squamous cell carcinomas
(SCC) (n=60) were analysed separately. Analysis of chromosome
X was conducted in the female data set (AC n=23 and SCCs
n=17). Chromosome Y, which does not contain any known
miRNA genes, was not examined. Selected thresholds for all
analyses are summarised in Table S1.
Identifying miRNAs within Regions of ArrayCGH Detected
Chromosomal Aberration
474 human miRNAs from Sanger miRBase Version 9.0
(http://microrna.sanger.ac.uk/) [30,31,32] were physically
mapped onto the arrayCGH dataset using miRNA precursor
chromosome number and nucleotide position, effectively position-
ing them between proximal and distal flanking arrayCGH probes.
MiRNA genes were classified as having copy number
aberrations if both flanking arrayCGH probes were: i) located
within 35kb (average spatial resolution of the platform) of the
miRNA or positioned within the miRNAs host gene; and ii)
identified as concordant gain or loss by both bioinformatic
methods (i.e. FC and ACE). These were then called as
‘‘significant’’ if both flanking probes were concordantly altered
in $25% but discordant in ,10% of primary tumours. This
produced a list of miRNAs in regions of copy number variation.
Validation of miRNAs from Independent Test Sets
We also interrogated published arrayCGH data from three
independent primary NSCLC cohorts [33,34,35] (Table S2).
Regions of chromosomal aberration were compiled and miRNAs
in areas of gain or loss were identified using genomic positioning
information as described above. This list of miRNAs was then
directly compared with candidates derived from the TPCH
(training) dataset to select those miRNAs within regions of
aberration consistent in the training set and at least one test set.
Prioritising miRNAs with Gene Dosage and Expression
Concordance
To select candidate miRNAs with concordantly altered dosage
and expression, we interrogated four public datasets of mature
miRNA expression from independent NSCLC cohorts [6,7,8,36]
(Table S3). Candidate miRNAs with changes in expression that
were concordant with their inferred copy number changes were
prioritised for further study.
Biological Verification of Aberrant miRNA Expression
Mature miRNA expression was measured using TaqMan qRT-
PCR assays (Applied Biosystems) in 39 paired NSCLCs and
normal lung (SCCs n=18 and ACs n=21) (Table 2). Total RNA
was isolated from 30 mg of tissue using TRIzol (Invitrogen) and
DNase treated (Ambion). MiRNA-specific reverse transcription for
miR-218 and U6 snRNA (internal control) used stem-loop
TaqMan primer/probe sets for real-time PCR (qRT-PCR) [37].
Triplicate TaqMan qRT-PCR assays were performed on a
Corbett Research Rotor-Gene 6000 with reference total RNA
Table 1. Clinicopathological characteristics of arrayCGH cohort.
Squamous Cell Carcinoma (n=60) Adenocarcinoma (n=72) All Primary NSCLCs (n=132)
Age (years) 66.2
(38.9–83.7)
64.7
(35.9–81.6)
65.4
(35.9–83.7)
Sex Male 43 49 92
Female 17 23 40
Stage Stage I 29 53 82
Stage II 23 10 33
Stage III 7 5 12
Stage IV 1 4 5
Smoking Status
a Current 26 30 56
Former 31 36 67
Never 3 6 9
aFormer smokers had quit smoking at least one year prior to lung resection, while current smokers continued smoking within one year of lung resection. Pack years were
calculated as number of cigarettes per day, multiplied by number of years of smoking, divided by 20. Never smokers had smoked less than 100 cigarettes in their life-time.
doi:10.1371/journal.pone.0012560.t001
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Panel, Ambion). Reaction efficiency and linear dynamic range was
determined for each assay. A ratio of miRNA expression to U6
snRNA expression was obtained using the Pfaffl method [38].
Correlating Dysregulated miRNA and Host Gene
Expression
Host gene expression was measured by qRT-PCR using SYBR
Green chemistry in the same cohort of 39 NSCLCs. DNase
treated total RNA were reverse transcribed using Superscript III
(Invitrogen). Primers were designed using Primer Express (Applied
Biosystems) and are listed in Table S4. Standard curves were
performed to determine the linear dynamic range and reaction
efficiency. All reactions were performed in triplicate on a Corbett
Rotorgene 6000 with melt curve analysis to confirm detection of a
single amplicon, with Universal Human Reference RNA (Strata-
gene) as reference. Relative gene expression was calculated and
normalised against internal controls (18S rRNA, ACTN4 and
BAT1) [39], using the Pfaffl method [38].
HPV Testing
Presence of HPV DNA was assessed in a cohort of 72 lung
SCCs accessed from TPCH Tumour Bank, including the 18 cases
with miR-218 expression data. HPV testing was performed by
Gribbles Pathology, Victoria, Australia, using the Genera
Biosystems PapType RUO Kit which detects 14 high-risk (16,
18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66 and 68) and two low
risk (6 and 11) HPV subtypes. This assay is based on 2 rounds of
PCR amplification of HPV and control gene DNA (alkali myosin
light chain protein) with addition of a fluorescent reporter dye and
utilises silica detection beads which fluoresce when hybridised to
its specific target DNA.
Statistical Analysis
Statistical analyses were performed as above or with SPSS
Version 13.0 (SPSS Inc Chicago, IL, USA) using Mann-Whitney
U and Pearson correlations. p values ,0.05 were considered
statistically significant. Survival analysis was undertaken with log
rank statistic of constructed Kaplan-Meier curves.
MiRNA Target Prediction and Pathway Analysis
Predicted mRNA targets of miR-218 were identified by using
four online miRNA target prediction programs: PicTar (5 species
conservation) [40], TargetScan 4.1 [41,42,43], miRBase Targets
Version 5 [30,31,32] and miRNAMap 2.0 [44,45]. Over-
represented gene ontologies (GO) and functional classes for
putative target genes of miR-218 predicted by two or more of
the algorithms were identified using the Database for Annotation,
Table 2. Clinicopathological characteristics of miR-218 validation cohort.
Squamous Cell Carcinoma Adenocarcinoma All Primary NSCLCs
(n=18) (n=21) (n=39)
Age (years) 66.5 67.6 67.1
(range) (44.4–83.7) (47.3–81.6) (44.4–83.7)
Sex Male 12 14 26
Female 6 7 13
Stage Stage I 5 15 20
Stage II 11 2 13
Stage III 2 3 5
Stage IV 0 1 1
Smoking Current 7 7 14
Status
a Former 8 11 19
Never 3 3 6
Asbestos Exposure Exposed (.20AB/gww) 5 10 15
Low Exposure (1–20AB/gww) 0 1 1
No Exposure (0AB/gww) 13 10 23
HPV DNA HPV 16 0 – –
HPV 18 1 – –
HPV 31 1 – –
Negative 16 – –
Recurrence Rec (3–18 months) 7 12 19
Non-Rec (.36 months) 8 7 15
Excluded 3 2 5
Survival Alive 7 6 13
Deceased 11 15 26
Survival Duration (months) (range) 24.7 (6.6–62.4) 25.3 (4.3–84.6) 25.1 (4.3–84.6)
aFormer smokers had quit smoking at least one year prior to lung resection, while current smokers continued smoking within one year of lung resection. Pack years
were calculated as number of cigarettes per day, multiplied by number of years of smoking, divided by 20. Never smokers had smoked less than 100 cigarettes in their
life-time. Abbreviations: Rec, Recurrence; Non-Rec, Non-Recurrent.
doi:10.1371/journal.pone.0012560.t002
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release) gene-GO enrichment analysis (ranked by the Expression
Analysis Systematic Explorer (EASE) score threshold) and gene
functional classification (performed with the highest stringency
setting) [46,47]. Ingenuity Pathway Analysis (IngenuityH Systems,
www.ingenuity.com) was performed on both the entire miR-218
target gene list and a prioritised list of miR-218 targets found to be
enriched $2.0 by DAVID gene functional classification.
Results
MiRNAs are Located in Regions of Genomic Alteration in
Lung Cancer
From TPCH arrayCGH data (training set), 89 of 474 (19%)
miRNAs were within chromosomal regions deleted (41 miRNAs)
or gained (48 miRNAs) in 132 primary NSCLC (Table S5).
Within the SCC subtype, 77 miRNAs were associated with DNA
copy number changes, with 40 miRNAs in areas of gain and 37 in
regions of loss. Twenty-six miRNAs were identified for ACs, with
21 and five miRNAs in regions of gain and loss respectively.
Fourteen miRNAs were located within regions of copy number
variation common to both SCC and ACs (one associated with
DNA loss and 13 associated with DNA gain). On the X
chromosome, five and four miRNAs were found to be associated
with regions of loss in ACs and SCCs respectively.
Validation of Candidate NSCLC miRNAs from Public Data
Test Sets
MiRNA dosage. To validate candidate miRNAs, we repeated
the positional mapping analysis using published independent
arrayCGH data test sets [33,34,35] and found 51 miRNAs; 28
and 23 miRNAs located within regions of gain or loss respectively
(Table S6). Eighteen of these wereamong the 89 miRNAs identified
frompositionalmappingtoarrayCGH(Figure1).NomiRNAswere
found to be located in genomic regions of copy number variation
that werediscordantbetweenourcohort(trainingset)andpublished
arrayCGH cohorts (test sets).
MiRNA Expression. To enrich for miRNAs with concordant
dysregulated expression and dosage, we reviewed the literature
and found 80 mature miRNAs reported to have altered expression
levels (44 increased, 32 decreased and four with conflicting reports)
in primary NSCLCs [6,7,8,36], 16 were represented in the 89
miRNA set with 10 showing expression dysregulation concordant
with predicted miRNA gene copy number change. Seven miRNAs
were among the 51 miRNAs identified from published arrayCGH
studies, but only three had concordant miRNA expression and
dosage between the public datasets. Two miRNAs, miR-218 and
miR-216, were common to training and all test sets, however, only
miR-218 demonstrated concordant loss of copy number and
expression (Figure 1). Expression levels of 38/89 candidate
NSCLC miRNAs and 19/51 published arrayCGH NSCLC
miRNAs have only recently been annotated in miRBase and
have not yet been studied in lung cancer.
MiR-218 Host Genes are in Regions of Copy Number Loss
in NSCLC
MiR-218 is produced from two unique miRNA precursors (hsa-
mir-218-1; MI0000294 and hsa-mir-218-2; MI0000295), encoded
in separate genomic locations, 4p15.31 and 5q35.1 respectively.
Both precursors are intragenic, with mir-218-1 situated within
intron 15–16 or 14–15 of SLIT2 (Slit Homolog 2) and mir-218-2
residing within intron 14–15 of SLIT3 (Slit Homolog 3) (Figure 1).
Mir-218-2 was identified as within a region of copy number loss in
.25% of SCCs but only .15% of ACs with average fold losses of
SLIT3 flanking probes 21.205 (range 22.23 to 21.11) and 21.115
(range 21.85 to +1.39) respectively. However, mir-218-1 was
located in a region of loss unique to SCCs, with an average fold loss
of SLIT2 flanking probes 21.13 (range 21.95 to +1.29) (Table S7).
MiR-218 Expression is Reduced in NSCLCs Compared
with Paired Normal Lung
To confirm decreased miR-218 dosage and expression in lung
cancer, we measured mature miR-218 expression in 21 ACs and
18 SCCs from our arrayCGH training set and their paired normal
lung. MiR-218 expression was down-regulated in 85% (33/39) of
NSCLC tumours compared with paired normal lung. Statistically
significant decreases were observed in both SCCs (mean
FC=24.4, p,1.0e-4) and to a lesser extent ACs (mean
FC=22.0, p=0.001) (Figure 2a).
Reduced miR-218 Expression is Associated With SLIT2
and SLIT3 Copy Number Loss
Correlation of miR-218 expression with host gene (SLIT2 and
SLIT3) arrayCGH probe copy number found the majority of
samples (31/39, 79.5%) demonstrated miR-218 down-regulation
with a decrease in SLIT2 and/or SLIT3 copy number however the
correlation was not significant (p.0.05; Pearson) (Figure S1a).
Complete concordance, that is, a reported loss of both host genes
plus a decrease in miR-218 expression, was observed in 55.6%
(10/18) SCCs and 38.1% (8/21) of ACs.
Figure 1. Identification of miR-218 from concordant copy
number variation and gene expression from independent data
sets. Expression levels of 38/89 candidate miRNAs and 19/51 published
arrayCGH miRNAs have not been studied due to their recent inclusion
in miRBase. The genomic location of miR-218 within its two host genes,
SLIT2 and SLIT3, is also illustrated.
doi:10.1371/journal.pone.0012560.g001
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mRNA Expression
To confirm predicted host gene down-regulation, we measured
SLIT2 and SLIT3 expression in 37 of the 39 NSCLC samples and
compared it with their paired normal lung tissue (19 ACs and 18
SCCs). As expected, SLIT2 and SLIT3 down-regulation was
observed in 36/37 and 34/37 NSCLCs respectively, with
statistically significant down-regulation of both SLIT2 and SLIT3
expression in both ACs and SCCs (p,0.001) (Figure 2b).
SLIT2 copy number loss plus reduced expression was observed
in 83% (15/18) SCCs and 79% (15/19) AC. Whilst SLIT3
demonstrated copy number and expression concordance in 83%
(15/18) SCCs but only 53% (10/19) ACs. For both SLIT2 and
SLIT3, the relationship between host gene expression and copy
number was not significant (p.0.05; Pearson) (Figure S1b).
To determine whether this intragenic miRNA is co-regulated
with host gene expression, we examined miR-218 and SLIT2/
SLIT3 expression levels. Concordant down-regulation of miR-218,
SLIT2 and SLIT3 was observed in 15/18 (83.3%) SCCs and 15/
19 (79%) ACs. Notably, one AC had concordant increases in miR-
218, SLIT2 and SLIT3 expression with CN loss of only SLIT3.I n
SCCs, miR-218 was moderately correlated with SLIT2 (R=0.496,
p=0.036) and SLIT3 (R=0.459, p=0.055), however, only SLIT2
was statistically significant. For ACs, weak-moderate correlations
were detected (SLIT2: R=0.378, p=0.111; SLIT3: R=0.297,
p=0.216) but these were not statistically significant (Figure S1c).
MiR-218, SLIT2 and SLIT3 Downregulation is Associated
with SLIT2 and SLIT3 Gene Dosage
Next, we compared SLIT2 and SLIT3 copy number with miR-
218, SLIT2 and SLIT3 expression to determine if their expression
was due to gene dosage. The 15 ACs and 15 SCCs found to have
concomitant reduced miR-218 and host gene expression also
demonstrated copy number loss in SLIT2 and/or SLIT3.
Complete concordance (loss of both host genes plus a decrease
in miR-218 expression) between SLIT2 and SLIT3 copy number
and miR-218, SLIT2 and SLIT3 expression, was observed in 9/19
(47.4%) ACs and 10/18 (55.6%) SCCs (Figure S2 and Table S8).
For one AC and two SCCs, miR-218 expression was increased
despite reduced host gene copy numbers and expression.
Association of miR-218 with Clinicopathological
Phenotypes
Smoking History. Compared to normal lung tissue, miR-
218 expression was significantly decreased in tumours of current
(SCC: FC-4.4; AC: FC-4.1; p,0.05) and former (SCC: FC-5.1;
AC: FC-1.9; p,0.05) smokers for both subtypes of NSCLC
(Figure 3a) but no decrease was observed in never smokers (albeit
small sample: SCC n=3, ACs n=3). No significant associations
were demonstrated between miR-218 expression and total number
of pack years smoked (in current and former smokers) or time since
quitting smoking (former smokers) in SCCs or ACs (data not
shown).
HPV Status. A large cohort of SCCs (n=72) were screened
to detect the presence of HPV DNA, with 9% (8/72) of these lung
SCCs testing positive. HPV subtypes identified were potentially
oncogenic, including types 16 (4/8), 18 (3/8) and 31 (1/8). For 18
SCCs with miR-218 expression data, 9% (2/18) tested positive for
HPV (subtypes 18 and 31) (Table 2) and HPV status not found to
be associated with a reduction in miR-218 expression (Figure 3b).
Asbestos. Altered miR-218 expression in NSCLC was also
examined in relation to asbestos exposure. Asbestos fibre burden
has previously been assessed for this cohort, and tumours with
.20 asbestos bodies per gram wet weight lung tissue (AB/gww)
were considered ‘asbestos exposed’ and those with 0 AB/gww
were considered to be ‘not exposed’ [28]. Altered miR-218
expression was not found to be associated with asbestos exposure
(Figure 3c) nor asbestos fibre burden (number of AB/gww lung
tissue - data not shown).
Recurrence and Survival. Following the earlier publication
by Larsen et al [26,27], recurrent NSCLCs were those that had
recurred within 3–18 months post-surgical resection and non-
recurrent subjects were those who had remained disease free for a
period of at least 36 months post-resection. No association was
observed between miR-218 expression levels and disease
recurrence or NSCLC survival post-resection (Figure 3d–e).
Figure 2. Expression of miR-218 and its host genes in primary NSCLCs and their paired normal lung. *p,0.05; **p,0.01. (a) Down-
regulation of miR-218 expression was observed in both ACs (FC -2; p=0.001; Z score =23.258) and SCCs (FC 24.365; p,0.0001; Z score =24.406).
(b) A reduction in host gene expression was observed in both ACs (SLIT2:F C212.77, p,0.0001, Z score =24.277; SLIT3:F C213.73, p,0.0001, Z
score =23.839) and SCCs (SLIT2:F C210.85, p,0.0001, Z score =25.182; SLIT3:F C25.46, p,0.0001, Z score =24.540). Abbreviations: FC, Fold
change.
doi:10.1371/journal.pone.0012560.g002
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Carcinogenesis
We identified predicted target genes of miR-218 using four
online miRNA target prediction algorithms. PicTar [40] and
miRNAMap 2.0 [44,45] identified 575 and 688 target genes
respectively, with 645 conserved sites and 133 poorly conserved
sites. TargetScan 4.1 [41,42,43] and miRBase Targets V5
[30,31,32] reported 570 and 946 miR-218 target sites respectively,
where multiple target sites could be present in the one gene. In
total, 1794 individual target genes were identified by these four
target prediction algorithms (578 identified by two or more of the
algorithms) (available on request).
Gene ontologies and biological function of the 578 target genes
were explored using DAVID (April 2008 Release) to determine
biological relevance [46,47]. GO enrichment analysis revealed
that biological processes such as cell adhesion, protein modifica-
tions and transport, development and cell signalling were over-
represented amongst miR-218 targets (p,0.001). Over-represent-
ed molecular functions (p,0.01) were predominantly focused on
protein binding function, in particular to actin, cytoskeletal
proteins, cyclic nucleotides, protein phosphatase 2A, cAMP, and
metal ions. Similar to gene ontology analysis, functional
annotation clustering reflected enrichment of groups of genes
largely involved in cell adhesion (enrichment score =4.66),
protein modification relating to ubiquitin cycle (enrichment scores
=3.67 and 3.33) or kinase activity (enrichment score =2.88), and
regulation of transcription (including proto-oncogenes, enrichment
score =2.22) (Table S9).
Network analysis of the 578 target genes by Ingenuity Pathway
Analysis identified 39 gene networks involved in biological
functions such as cell-to-cell signalling, amino acid metabolism,
post-translational modifications, cancer and respiratory system
development and function (p,0.05) (Figure S3a and Table S10).
Canonical pathway analysis found numerous cancer signalling
pathways including Wnt/b-catenin signalling, ERK/MAPK
signalling and Notch signalling (p,0.05) (Figure S3b). To attempt
to define a more specific network or pathway associated with miR-
218, we performed a focused analysis using 121 enriched genes
($2.00) identified with functional annotation clustering in
DAVID. This identified 10 gene networks that reflected similar
cancer-related biological functions to those identified using the
larger target gene list (Table S10). For instance, in the ‘gene
expression, cancer and cell morphology’ network, miR-218 may
target genes directly and indirectly linked to two oncogenes, MYC
and SRC (Figure S4).
Discussion
We demonstrate that genomic profiling can be used to identify
cancer related miRNAs. We found 19% of miRNAs were located
in regions of copy number variation in primary NSCLC, which is
relatively lower than ovarian (37%), breast (73%) and melanoma
(86%) [48]. Aside from being different tumour types, this may be
due to more recently identified miRNAs not highly represented in
cancer-associated genomic regions, our high stringency bioinfor-
matics, or both. We limited ourselves to miRNAs located within
Figure 3. Relationship of miR-218 expression to smoking (a),
HPV (b), asbestos (c), recurrence (d) and survival (e). *p=0.05;
**p=0.01. Abbreviations: FC, Fold change. Statistically significant
downregulation of miR-218 expression was observed in current and
former smokers of both NSCLC subtypes. No significant associations
were observed between miR-218 expression and HPV, asbestos, disease
recurrence or survival.
doi:10.1371/journal.pone.0012560.g003
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resolution of the platform (35 kb), because the array used in this
study did not have any probes directly representing any miRNA
genes. Next generation higher-resolution arrayCGH platforms will
refine this approach specifically detecting miRNA genomic loci.
Nonetheless, we successfully identified 89 potential lung cancer
miRNAs, including established oncogenic and tumour suppressing
miRNAs. Three members of the known tumour suppressing let-7
family of miRNAs were identified in regions of loss (let-7g, let-7f-2
and miR-98), and oncogenic miR-21 was found within a genomic
region of amplification.
Over half of the 89 miRNAs (65%) are intragenic; interestingly,
many of the host genes have reported roles in cancer. For example,
MCM7 (minichromosome maintenance protein 7) is the host gene
for three of the miRNAs (miR-25, miR-93 and miR-106b) we
identified and has been reported to be amplified or over-expressed
in human malignancies including prostatic, pancreatic, thyroid,
cervical and colorectal cancers [49,50,51,52,53,54]. In prostate
cancer, increased levels of these 3 miRNAs occurred with
amplified and over-expressed MCM7 [55]. This observation
supports the idea proposed that miRNAs and their host genes may
be jointly affected by copy number changes [48].
Only one ofthe89 miRNAs, miR-218,demonstrated concordant
changesin copy numberand expression. Additional candidatesmay
be identified with publication of new miRNA expression studies in
NSCLC as half of the miRNAs with concordant copy number
changes (10/18) were excluded from this first pass analysis as their
mature expression levels have not been measured. Furthermore,
miRNAs are subject to complex regulatory mechanisms so it is not
surprising to observe numerous miRNAs with discordant copy
number and expression (such as miR-216). However, as with any
genome-wide approach for gene discovery, there is the potential to
identify false positives. We have attempted to alleviate this risk by
using high stringency criteria for identification of candidate
miRNAs from our aCGH data and subsequently using published
NSCLC cohorts with copy number and miRNA expression data to
independentlyvalidate thesecandidates.Assuch,miR-218 emerged
as a strong candidate tumour suppressor, within a region of copy
number loss in greater than two NSCLC studies and with
demonstrated loss of expression in a third independent cohort.
Produced from two separate precursors, miR-218 is found
within host genes SLIT2 and SLIT3, with both the miRNA and its
host genes demonstrating reduced expression in the majority
(80%) of NSCLCs. Zhang et al reported copy number losses of mir-
218-1 and SLIT2 in ovarian (16%), breast (36%) and melanoma
(33%), however, the alternative precursor and host gene were not
mentioned [48]. It has been suggested that intronic miRNAs share
host gene transcriptional regulatory control with resulting co-
expression [22,23]. Despite noting a reduction in both miR-218
and host gene expression in the majority of NSCLCs, only a
moderate correlation between miR-218 and SLIT2 expression was
detected, with no significant relationship with SLIT3. This may be
a reflection of disproportionate production of miR-218 from each
genomic site, alterations in miRNA biogenesis or miR-218 may
have a promoter separate from its host gene. Similarly, no
significant associations between miR-218 or host gene expression
with host gene copy number were identified, but we found that
complete concordance (copy number loss of both host genes with
reduced miRNA and host gene expression) observed in 51% of
lung cancers studied. These findings would suggests that genetic
loss may contribute to the observed reduction in miR-218, SLIT2
and SLIT3 expression, however it is likely that aberrations in
multiple regulatory mechanisms are involved, including alterations
to miRNA biogenesis and epigenetic controls. For example,
altered epigenetic control of SLIT2 and SLIT3 has also been
reported in lung cancer with hypermethylation of SLIT2 and to a
lesser extent SLIT3 [56,57]. Thus, epigenetic silencing is an
alternative or additional ‘hit’, and strengthens the case for miR-
218 and its host genes as potential tumour suppressor genes.
Additional support for a role for miR-218 in NSCLC comes
from the potential association between miR-218 downregulation
and cigarette smoke exposure. Further, Schembri et al has also
demonstrated a link between miR-218 downregulation and
smoking; exposing human bronchial epithelial cells to cigarette
smoke extract decreased miR-218 expression levels [58]. Our
observation that in both subtypes of NSCLC, miR-218 expression
is significantly reduced in subjects with a history of cigarette
smoking, provides additional support the notion that miR-218
may be involved in tobacco-related carcinogenesis [58]. However,
the number of never smokers used in this study is insufficient to
confirm this relationship and further investigation is required with
larger cohorts and functional validation to explore a causative
relationship. We also examined whether the decrease in miR-218
expression was associated with asbestos, a well known lung
carcinogen, but found no significant correlation. As miR-218 may
play a role in metastasis, with Leite et al reporting high levels of
miR-218 in high grade prostate cancer compared to significantly
reduced levels in metastatic prostate cancers [59], we examined
the survival of our cases with miR-218 dysregulation. In lung
cancer, we found no relationship between miR-218 expression
levels and NSCLC recurrence or patient survival.
MiR-218 has also been shown to be downregulated in cervical
carcinoma through the action of the HPV 16 E6 oncogene and may
be important in early cervical tumourigenesis [25]. We have
previously identified a limited association for HPV infection in lung
cancer, with reports of HPV prevalence ranging from 5–22% [60,61].
We did not find any link between HPV status and miR-218 expression
but one reason may be that neither of our HPV positive samples were
HPV type 16, and reduced miR-218 has only been reported with the
HPV 16 – E6 oncogene. However, the small numbers preclude strong
conclusions and more samples need testing. MiR-218 has also been
reported to be reduced in gastric cancer, with reduced expression
linked to Helicobacter pylori infection and carcinogenesis [62].
Target prediction found miR-218 can target numerous
oncogenes, such as KIT, RET, BCL9, DCUN1D1 and PDGFRA.
Gene ontology and functional annotation clustering of the
predicted targets revealed enrichment of genes involved in cell
adhesion, protein modification, development, cell signalling and
regulation of transcription, all processes that may contribute to
carcinogenesis. These findings were reflected in the Ingenuity
Pathway Analysis, with miR-218 potentially regulating genes
involved in cancer-related biological functions and three recog-
nised cancer signalling pathways. Focused pathway analysis also
revealed that miR-218 may regulate genes directly and indirectly
related to MYC and SRC, two well characterised oncogenes
[20,21,63,64,65]. Recent studies have begun to authenticate miR-
218 target genes, including LAMB3 (laminin-5 b3) [25], ECOP
(Epidermal growth factor receptor-coamplified and overexpressed
protein) [58,62] and transcription factor MAGF (v-maf musculo-
aponeurotic fibrosarcoma oncogene homolog G) [58].
In summary,arrayCGH cancer datasetsare increasingly available
with unbiased probes or selected cancer associated genes. We
combined bioinformatic and experimental approaches to test
whether miRNAs located in regions of gene dosage alteration had
concordant altered expression, and therefore of importance. With
this approach we identified putative tumour suppressor miR-218,
experimentally confirmed its downregulation in NSCLC, and
provided additional support for an association between reduced
microRNA-218 in NSCLC
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relevant cancer-related target genes and pathways targeted by miR-
218, supporting a potential role as a tumour suppressor gene for
NSCLC, especially SCCs. Nonetheless, further evidence including
structural mutations and demonstrable tumour suppressor functions
should be gathered before miR-218 can be appropriately designated
as a tumour-suppressor gene for lung cancer.
Supporting Information
Figure S1 Relationship between host gene copy number, host
gene expression and miR-218 expression in lung adenocarcinomas
and squamous cell carcinomas. *p=0.05. (a) No significant
Pearson correlation was observed for host gene copy number
and miR-218 expression in SCCs (SLIT2: 20.282, p=0.257;
SLIT3: 20.111 p=0.661) or ACs (SLIT2: 20.078 p=0.737;
SLIT3: 20.107, p=0.646). (b) No significant Pearson correlation
was observed for host gene copy number and expression in SCCs
(SLIT2: 20.389, p=0.111; SLIT3: 20.265 p=0.288) or ACs
(SLIT2: 0.009 p=0.970; SLIT3: 0.249, p=0.304). (c) A
significant Pearson correlation was observed between miR-218
expression and SLIT2 expression in SCCs (0.496, p=0.036) but
not ACs (0.378, p=0.111). No significant correlation was observed
between miR-218 expression and SLIT3 expression (SCC: 0.459,
p=0.055; AC: 0.297, p=0.216).
Found at: doi:10.1371/journal.pone.0012560.s001 (1.42 MB TIF)
Figure S2 MiR-218, SLIT2 and SLIT3 expression and SLIT2
and SLIT3 copy number in lung squamous cell carcinomas (a) and
adenocarcinomas (b). Complete concordance (loss of both host
genes plus a decrease in miR-218 expression) between SLIT2 and
SLIT3 copy number and miR-218, SLIT2 and SLIT3 expression,
was observed in 9/19 (47.4%) ACs and 10/18 (55.6%) SCCs. For
one AC and two SCCs, miR-218 expression was increased despite
reduced host gene copy numbers and expression.
Found at: doi:10.1371/journal.pone.0012560.s002 (0.30 MB TIF)
Figure S3 Ingenuity Pathway Analysis miR-218. Core analysis
for 578 predicted miR-218 target genes. (a) Top 20 biological
functions. Threshold bar is set at significance of p,0.05 and -
log(p-value) of 1.3. (b) Top 20 canonical pathways. Threshold bar
is set at significance of p,0.05 and -log(p-value) of 1.3. Line
illustrates the ratio of miR-218 target genes in the pathway divided
by the total number of genes in the pathway. Red circles highlight
cancer-associated functions or pathways.
Found at: doi:10.1371/journal.pone.0012560.s003 (2.24 MB TIF)
Figure S4 Network of enriched miR-218 target genes linked to
the biological functions of gene expression, cancer and cell
morphology identified from Ingenuity Pathway Analysis. MiR-218
may target genes (coloured orange) directly and indirectly linked to
two well known oncogenes, MYC and SRC (coloured red). For
clarity, additional miRNAs and their targets involved in this
network were removed therefore only 9 of the 11 miR-218 targets
are shown. RELN is also a predicted target of miR-218 but was
not included in the enriched gene list.
Found at: doi:10.1371/journal.pone.0012560.s004 (2.29 MB TIF)
Table S1 Selected thresholds for identification of chromosomal
aberrations in arrayCGH data. Abbreviations: SCC, Squamous
Cell Carcinoma; AC, Adenocarcinoma; FC, Fold change; ACE,
Analysis of Copy Errors; FDR, False Discovery Rate.
Found at: doi:10.1371/journal.pone.0012560.s005 (0.03 MB
DOC)
Table S2 ArrayCGH Publications used for miRNA prioritisa-
tion. Abbreviations: SCC, Squamous Cell Carcinoma; AC,
Adenocarcinoma; AdSq, Adenosquamous Carcinoma; BAC,
Bronchioalveolar Carcinoma; SCLC, Small Cell Lung Carcino-
ma; LC, Large Cell Carcinoma.
Found at: doi:10.1371/journal.pone.0012560.s006 (0.03 MB
DOC)
Table S3 MiRNA Expression studies used for miRNA prior-
itisation. Abbreviations: SCC, Squamous Cell Carcinoma; AC,
Adenocarcinoma; AdSq, Adenosquamous Carcinoma; LC, Large
Cell Carcinoma.
Found at: doi:10.1371/journal.pone.0012560.s007 (0.04 MB
DOC)
Table S4 Primers for host gene qRT-PCR
Found at: doi:10.1371/journal.pone.0012560.s008 (0.03 MB
DOC)
Table S5 Candidate miRNAs identified from positional ar-
rayCGH analysis. Abbreviations: AC, Adenocarcinoma; SCC,
Squamous Cell Carcinoma.
Found at: doi:10.1371/journal.pone.0012560.s009 (0.12 MB
DOC)
Table S6 Candidate miRNAs identified from public arrayCGH
data.
Found at: doi:10.1371/journal.pone.0012560.s010 (0.07 MB
DOC)
Table S7 Summary of arrayCGH analysis for mir-218-1 and
mir-218-2.
Found at: doi:10.1371/journal.pone.0012560.s011 (0.07 MB
DOC)
Table S8 Summary of miR-218 expression and SLIT2/SLIT3
expression and copy number changes. Abbreviations: FC, Fold
Change; SCC, Squamous Cell Carcinoma; AC, Adenocarcinoma.
Found at: doi:10.1371/journal.pone.0012560.s012 (0.07 MB
DOC)
Table S9 Enriched miR-218 target gene groups identified by
gene functional classification in DAVID.
Found at: doi:10.1371/journal.pone.0012560.s013 (0.03 MB
DOC)
Table S10 Top 10 networks for predicted miR-218 target genes
from ingenuity pathway analysis.
Found at: doi:10.1371/journal.pone.0012560.s014 (0.03 MB
DOC)
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